Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 9/27/2017

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Identification of Perinatal HIV Exposure  (Last updated April 27, 2017; last reviewed April 27, 2017)

Panel’s Recommendations

• HIV testing early in pregnancy is recommended as standard of care for all pregnant women in the United States (AII).

• Repeat HIV testing in the third trimester, before 36 weeks’ gestation, should be considered for all HIV-seronegative pregnant women and is recommended for pregnant women who are at high risk of HIV infection (AII).

• Expedited HIV testing at the time of labor or delivery should be performed for any woman with undocumented HIV status; testing should be available 24 hours a day, and results available within 1 hour. If results are positive, intrapartum and infant postnatal antiretroviral (ARV) drug prophylaxis should be initiated immediately, pending results of supplemental HIV testing (AII).

• Women who have not been tested for HIV before or during labor should undergo expedited HIV antibody testing during the immediate postpartum period or their newborns should undergo expedited HIV antibody testing. If results in mother or infant are positive, infant ARV drug prophylaxis should be initiated immediately, and the mothers should not breastfeed unless supplemental HIV testing is negative (AII). In infants with initial positive HIV viral tests (RNA, DNA), prophylaxis should be stopped and antiretroviral therapy initiated.

• When acute maternal HIV infection is suspected during pregnancy, in the intrapartum period, or while breastfeeding, initial testing should be performed with an antigen/antibody combination immunoassay; if the initial testing was performed with an HIV antibody test or supplemental testing is negative, an additional virologic test (RNA, DNA) may be necessary to diagnose HIV infection (AII).

• Results of maternal HIV testing should be documented in the newborn’s medical record and communicated to the newborn’s primary care provider (AIII).

• Infant HIV antibody testing to determine HIV exposure should be considered for infants in foster care and adoptees for whom maternal HIV infection status is unknown (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion
† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
<table>
<thead>
<tr>
<th>Panel's Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Virologic assays (i.e., HIV RNA and HIV DNA nucleic acid tests) that directly detect HIV must be used to diagnose HIV infection in children younger than 18 months with perinatal HIV exposure; HIV antibody tests should not be used (AII).</td>
</tr>
<tr>
<td>• Virologic diagnostic testing is recommended for all infants with perinatal HIV exposure at the following ages:</td>
</tr>
<tr>
<td>• 14 to 21 days (AII)</td>
</tr>
<tr>
<td>• 1 to 2 months (AII)</td>
</tr>
<tr>
<td>• 4 to 6 months (AII)</td>
</tr>
<tr>
<td>• Additional virologic diagnostic testing should be considered for infants at higher risk of perinatal HIV transmission at birth (AIII) and 2 to 4 weeks after cessation of antiretroviral prophylaxis (BIII).</td>
</tr>
<tr>
<td>• A positive virologic test should be confirmed as soon as possible by a repeat virologic test on a second specimen (AII).</td>
</tr>
<tr>
<td>• Definitive exclusion of HIV infection in non-breastfed infants is based on 2 or more negative virologic tests, with 1 obtained at age ≥1 month and 1 at age ≥4 months, or 2 negative HIV antibody tests from separate specimens obtained at age ≥6 months (AII).</td>
</tr>
<tr>
<td>• Many experts confirm the absence of HIV infection at 12 to 18 months of age in children with prior negative virologic tests by performing an antibody test to document loss of maternal HIV antibodies (BIII).</td>
</tr>
<tr>
<td>• Children aged 18 to 24 months with perinatal HIV exposure may have residual maternal HIV antibodies; definitive exclusion or confirmation of HIV infection in children in this age group who are HIV antibody-positive should be based on an HIV nucleic acid test (see Diagnostic Testing in Children with Perinatal HIV Exposure in Special Situations) (AII).</td>
</tr>
<tr>
<td>• Diagnostic testing in children with non-perinatal exposure only or children with perinatal exposure aged &gt;24 months relies primarily on the use of HIV antibody (or antigen/antibody) tests; when acute HIV infection is suspected, additional testing with an HIV nucleic acid test may be necessary to diagnose HIV infection (AII).</td>
</tr>
</tbody>
</table>

Note: The National Clinical Consultation Center provides consultations on issues related to the management of perinatal HIV infection (1-888-448-8765; 24 hours a day, 7 days a week).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
Panel’s Recommendations

- Absolute CD4 T lymphocyte (CD4) cell count and plasma HIV RNA (viral load) should be measured at the time of diagnosis of HIV infection and, if a child is not started on antiretroviral therapy (ART) after diagnosis, **this monitoring should be repeated** at least every 3 to 4 months thereafter (AIII).

- Antiretroviral (ARV) drug-resistance testing is recommended at the time of HIV diagnosis, before initiation of therapy, in all treatment-naive patients (AII). Genotypic resistance testing is preferred for this purpose (AIII).

- After initiation of ART, or after a change in ART regimen, children should be evaluated for clinical adverse effects and to support treatment adherence within 1 to 2 weeks, with laboratory testing for toxicity and viral load response recommended at 2 to 4 weeks after treatment initiation (AIII).

- Children on ART should be monitored for therapy adherence, effectiveness, and toxicities routinely (every 3 to 4 months) (AII*).

- Additional CD4 cell count and plasma viral load monitoring should be performed for evaluation of children with suspected clinical, immunologic, or virologic deterioration or to confirm an abnormal value (AIII). CD4 cell count can be monitored less frequently (every 6–12 months) in children and youth who are adherent to therapy and have CD4 cell value well above the threshold for opportunistic infection risk, sustained viral suppression, and stable clinical status for more than 2 to 3 years (AII).

- Phenotypic resistance testing should be used (usually in addition to genotypic resistance testing) for patients with known or suspected complex drug resistance mutation patterns, which generally arise after virologic failure of successive ART regimens (BIII).

- The absence of detectable resistance to a drug does not ensure that use of the drug will be successful, as mutations may not be detected once the drug has been discontinued. A history of all previously used ARV agents and available resistance test results must be reviewed when making decisions regarding the choice of new agents (AII).

- Viral coreceptor (tropism) assays should be used whenever the use of a CCR5 antagonist is being considered (AI*). Tropism assays should also be considered for patients who demonstrate virologic failure while receiving therapy that contains a CCR5 antagonist (AI*).

- Absolute CD4 cell count is recommended for monitoring immune status in children of all ages, with CD4 percentage as an alternative for children aged <5 years (AII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
### Treatment Recommendations for Initiation of Therapy in Antiretroviral-Naive Infants and Children with HIV

#### Panel Recommendations

<table>
<thead>
<tr>
<th>Age</th>
<th>Criteria</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;12 Months†</td>
<td>Regardless of clinical symptoms, immune status, or viral load</td>
<td>Urgent† treatment (AI except AI for ≥6 weeks to &lt;12 weeks of age)</td>
</tr>
<tr>
<td>1 to &lt;6 Years</td>
<td>CDC Stage 3-defining opportunistic illnesses(^c)</td>
<td>Urgent† treatment (AI*)</td>
</tr>
<tr>
<td></td>
<td>CDC Stage 3 immunodeficiency: CD4 &lt;500 cells/mm(^3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate HIV-related symptoms(^c)</td>
<td>Treat(^e) (AI)</td>
</tr>
<tr>
<td></td>
<td>CD4 cell count: 500–999 cells/mm(^3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asymptomatic or mild symptoms(^c) and CD4 cell count: ≥1000 cells/mm(^3)</td>
<td>Treat(^e) (BI*)</td>
</tr>
<tr>
<td>≥6 Years†</td>
<td>CDC Stage 3-defining opportunistic illnesses(^c)</td>
<td>Urgent† treatment (AI*)</td>
</tr>
<tr>
<td></td>
<td>CDC Stage 3 immunodeficiency: CD4 &lt;200 cells/mm(^3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate HIV-related symptoms(^c)</td>
<td>Treat(^b) (AI)</td>
</tr>
<tr>
<td></td>
<td>CD4 cell count: 200–499 cells/mm(^3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asymptomatic or mild symptoms(^c) and CD4 cell count: ≥500 cells/mm(^3)</td>
<td>Treat(^f) (BI*)</td>
</tr>
</tbody>
</table>

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials in children\(^†\) with clinical outcomes and/or validated endpoints; I\(^*\) = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children\(^†\) from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children\(^†\) with long-term outcomes; II\(^*\) = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children\(^†\) from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

\(^†\) Studies that include children or children and adolescents but not studies limited to post-pubertal adolescents

**Note:** Adherence should be assessed and discussed with children with HIV and their caregivers before initiation of therapy (AIII).

\(^*\) Treatment of infants ≤2 weeks is a more complex issue and an area of active investigation. See [Specific Issues in Antiretroviral Therapy for Neonates](https://aidsinfo.nih.gov/guidelines).

\(^\circ\) Within 1–2 weeks, including an expedited discussion on adherence

\(^\circ\) See Table 6 for definitions

\(^4\) CD4 cell counts should be confirmed with a second test to meet the treatment criteria before initiation of ART.

\(^\circ\) More time can be taken to fully assess and address issues associated with adherence with the caregivers and the child prior to initiating therapy. Patients/caregivers may choose to postpone therapy, and on a case-by-case basis, providers may elect to defer therapy based on clinical and/or psychosocial factors, with close patient monitoring.

\(^\circ\) For initiation of ART for adolescents aged ≥13 years and sexually maturity ratings or 4 or 5, see the [Adult and Adolescent Guidelines](https://aidsinfo.nih.gov/guidelines).

**Key to Acronyms:** CD4 = CD4 T lymphocyte; CDC = Centers for Disease Control and Prevention
What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children

Panel’s Recommendations

- Selection of an initial regimen should be individualized based on several factors, including characteristics of the proposed regimen, patient characteristics, and results of viral resistance testing (AIII).
- For treatment-naive children, the Panel recommends initiating antiretroviral therapy with 3 drugs, including either a boosted protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or integrase strand transfer inhibitor plus a dual-nucleoside/nucleotide reverse transcriptase inhibitor backbone (AI*).
- Table 7 provides a list of Panel-recommended regimens that are designated as Preferred, Alternative, or for use in Special Circumstances; recommendations vary by age, weight, and sexual maturity rating.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Specific Issues in Antiretroviral Therapy for Adolescents Living with HIV Infection

Panel’s Recommendations

- Antiretroviral therapy (ART) selection should take into account the adolescent’s individual needs and preferences (AIII).
- Reproductive health including preconception care and contraceptive methods, and safe sex techniques to prevent HIV transmission should be discussed regularly (AI).
- All adolescents, including those who are considering pregnancy, should be receiving maximally suppressive ART (AII).
- Providers should be aware of potential interactions between ART and hormonal contraceptives that could lower contraceptive efficacy (AII*).
- Pediatric and adolescent care providers should prepare adolescents for the transition into adult care settings (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
Adherence to Antiretroviral Therapy in Children and Adolescents Living with HIV *(Last updated April 27, 2017; last reviewed April 27, 2017)*

### Panel’s Recommendations

- Strategies to maximize adherence should be discussed before initiation of antiretroviral therapy (ART) and again before changing regimens *(AIII).*
- Adherence to therapy must be assessed and promoted at each visit, along with continued exploration of strategies to maintain and/or improve adherence *(AIII).*
- At least one method of measuring adherence to ART should be used in addition to monitoring viral load *(AIII).*
- Once-daily antiretroviral regimens and regimens with low pill burden should be prescribed whenever feasible *(AII*).

**Rating of Recommendations**: A = Strong; B = Moderate; C = Optional

**Rating of Evidence**: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Management of Medication Toxicity or Intolerance *(Last updated April 27, 2017; last reviewed April 27, 2017)*

### Panel’s Recommendations

- In children who have severe or life-threatening toxicity (e.g., a hypersensitivity reaction), all antiretroviral (ARV) drugs should be stopped immediately *(AIII).* Once symptoms of toxicity have resolved, antiretroviral therapy should be resumed with substitution of a different ARV drug or drugs for the offending agent(s) *(AII*).
- When modifying therapy because of toxicity or intolerance to a specific drug in children with virologic suppression, changing one drug in a multidrug regimen is permissible; if possible, an agent with a different toxicity and side-effect profile should be chosen *(AI*).
- The toxicity and the medication presumed responsible should be documented in the medical record and the caregiver and patient advised of the drug-related toxicity *(AIII).*
- In general, dose reduction is not a recommended option for management of ARV toxicity *(AII*).

**Rating of Recommendations**: A = Strong; B = Moderate; C = Optional

**Rating of Evidence**: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents but not studies limited to post-pubertal adolescents
Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy

**Panel's Recommendations**

- Children who have sustained virologic suppression on their current regimen should be regularly evaluated for opportunities to change to a new regimen that facilitates adherence, simplifies antiretroviral (ARV) administration, increases ARV potency, and decreases the risk of drug-associated toxicity (AII).

- Past episodes of antiretroviral therapy failure, tolerability, and all prior drug resistance testing results should be considered in order to avoid choosing new ARV drugs for which archived drug resistance would limit activity (AIII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
### Recognizing and Managing Antiretroviral Treatment Failure

**Panel’s Recommendations**

- The causes of virologic treatment failure—which include poor adherence, drug resistance, poor absorption of medications, inadequate dosing, and drug-drug interactions—should be assessed and addressed (AII).

- Perform antiretroviral (ARV) drug-resistance testing when virologic failure occurs, while the patient is still taking the failing regimen, and before changing to a new regimen (AI*).

- ARV regimens should be chosen based on treatment history and drug-resistance testing, including both past and current resistance test results (AI*).

- The new regimen should include at least 2, but preferably 3, fully active ARV medications with assessment of anticipated ARV activity based on past treatment history and resistance test results (AII*).

- The goal of therapy following treatment failure is to achieve and maintain virologic suppression, as measured by a plasma viral load below the limits of detection using the most sensitive assay (AI*).

- When complete virologic suppression cannot be achieved, the goals of therapy are to preserve or restore immunologic function (as measured by CD4 T lymphocyte values), prevent clinical disease progression, and prevent development of additional drug resistance that could further limit future ARV options (AII).

- Children who require evaluation and management of treatment failure should be managed by or in collaboration with a pediatric HIV specialist (AI*).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

### Considerations About Interruptions in Antiretroviral Therapy

**Panel’s Recommendations**

- Outside the context of clinical trials, structured interruptions of antiretroviral therapy are not recommended for children (AII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

† Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
### Panel’s Recommendations

- Routine evaluation of plasma concentrations of antiretroviral (ARV) drugs is not generally recommended in the management of children with HIV infection (BII).
- Targeted therapeutic drug monitoring of ARV drugs in children can be considered in the following scenarios (BII):
  - Use of ARV drugs with limited pharmacokinetic data and/or therapeutic experience in children;
- Use of patient pharmacogenetic profile for the selection of the dose of certain ARV drugs (e.g. efavirenz);
  - Significant drug-drug and food-drug interactions;
  - Suboptimal treatment response (e.g., lack of virologic suppression) in medication-adherent patients;
  - Suspected suboptimal absorption, distribution, metabolism, or elimination of the drug; or
  - Suspected concentration-dependent drug-associated toxicity.

### Rating of Recommendations

**A** = Strong; **B** = Moderate; **C** = Optional

### Rating of Evidence

**I** = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; **I** = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; **II** = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; **II** = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; **III** = Expert opinion

† Studies that include children or children/adolescents but not studies limited to postpubertal adolescents